tbuckley/cabot-search huggingface dataset:
COVD-20. COVID-19 INFECTION DURING CHEMOTHERAPY FOR MALIGNANT GLIOMA: OUTCOMES AMONG 3 PATIENTS
Authors: Esther Kim, Amily Koshy, Shannon Higgins, Andrew Lassman, Fabio Iwamoto
Journal: Neuro-Oncology (2020)

Abstract BACKGROUND Chemotherapy may increase risk of SARS-COV-2 infection and COVID-19 severity. METHODS A patient developed COVID-19 during chemotherapy for glioma. We retrospectively identified others diagnosed with COVID-19 during temozolomide or lomustine for glioma. RESULTS (1) A 64 year-old woman (index patient) with anaplastic oligodendroglioma received PCV 22 months previously. Baseline White Blood Cell (WBC) count was 4.2 and Absolute Neutrophil Count (ANC) was 2.7 K/uL. KPS was 90 without comorbidities. For recurrence she initiated temozolomide but developed fever on cycle 1 day 2. SARS-COV-2 PCR was positive. Further temozolomide was held. She is recovering as an outpatient. (2) A 27 year-old man with anaplastic astrocytoma received concurrent RT/temozolomide then 1 cycle of adjuvant temozolomide. Baseline WBC was 8.3, ANC 5.2, and KPS 90. Obesity, asthma, and pre-diabetes were comorbidities. Hyposmia/hypogeusia and low-grade fever began, in retrospect, during concurrent RT/temozolomide. PCR for SARS-COV-2 was negative 2 months after symptom onset; serology detected both IgG and IgM when WBC was 6.6 and ANC 4.0. Cycle 2 of adjuvant temozolomide was held until fever resolved (spontaneously); hyposmia/hypogeusia persist. (3) A 53 year-old man with glioblastoma previously received RT/temozolomide, then lomustine and bevacizumab for progression. WBC was 5.1, ANC 4.0, and KPS 60. He was obese. Fever, chills, and dyspnea developed on lomustine cycle 2 day 38. SARS-COV-2 PCR was positive. He was hospitalized and chemotherapy held; symptoms resolved 12 days after onset, but PCR continued to show detectable virus 32 days later. PCR became negative after 50 days total, and treatment resumed uneventfully. DISCUSSION All 3 patients recovered from SARS-COV-2 infection despite active temozolomide or lomustine chemotherapy. Normal ANC, high KPS, and early detection may have contributed to limited symptom severity and duration, despite obesity and other comorbidities in 2 cases. Detection changed management by delaying additional cycles of immunosuppressive chemotherapy until recovery.
Surgical Robot for Intraluminal Access: An<i>Ex Vivo</i>Feasibility Study
Authors: Ryu Nakadate, Tsutomu Iwasa, Shinya Onogi, Jumpei Arata, Susumu Oguri, Yasuharu Okamoto, Tomohiko Akahoshi, Masatoshi Eto, Makoto Hashizume
Journal: Cyborg and Bionic Systems (2020)

Early-stage gastrointestinal cancer is often treated by endoscopic submucosal dissection (ESD) using a flexible endoscope. Compared with conventional percutaneous surgery, ESD is much less invasive and provides a high quality of life for the patient because it does not require a skin incision, and the organ is preserved. However, the operator must be highly skilled because ESD requires using a flexible endoscope with energy devices, which have limited degrees of freedom. To facilitate easier manipulation of these flexible devices, we developed a surgical robot comprising a flexible endoscope and two articulating instruments. The robotic system is based on a conventional flexible endoscope, and an extrapolated motor unit moves the endoscope in all its degrees of freedom. The instruments are thin enough to allow insertion of two instruments into the endoscope channel, and each instrument has a bending section that allows for up-down, right-left, and forward-backward motion. In this study, we performed an ex vivo feasibility evaluation using the proposed robotic system for ESD in a porcine stomach. The procedure was successfully performed by five novice operators without complications. Our findings demonstrated the feasibility of the proposed robotic system and, furthermore, suggest that even operators with limited experience can use this system to perform ESD.
EPID-13. A POPULATION-BASED ANALYSIS OF CNS TUMOR DIAGNOSES, TREATMENT, AND SURVIVAL IN CONGENITAL AND INFANT AGE GROUPS
Authors: Muriel Hart, Amy Mellies, Alina Beltrami, Ahmed Gilani, Adam Green
Journal: Neuro-Oncology (2020)

Abstract BACKGROUND Congenital (&amp;lt;3 months) and infant (3 to 11 months) brain tumors are biologically different from tumors in older children, but epidemiology of these tumors has not been studied comprehensively. Insight into epidemiological differences could help tailor treatment recommendations by age and increase overall survival (OS). METHODS Population-based data from the SEER 18 registries was obtained for 14,493 0-19-year-olds diagnosed with CNS tumors between 1990 and 2015. Incidence, treatment, and survival were analyzed using Chi-square and Kaplan-Meier analyses. RESULTS Between the &amp;lt;3 month, 3–5 month, 6–11 month, and 1–19 year age groups, tumor type distribution differed significantly (p&amp;lt;0.001); high-grade glioma (HGG) was most common in the &amp;lt;3-month-olds, while low-grade glioma (LGG) was most common in the other groups. 5-year OS for all tumors was 36.7% (&amp;lt;3 months), 56.0% (&amp;lt;3–5 months), 63.8% (6–11 months), and 74.7% (1–19 years) (log rank p&amp;lt;0.001). OS by tumor type was worst for &amp;lt;3-month-olds with LGG, medulloblastoma, and other embryonal tumors; OS was worst for 3-5-month-olds with ependymoma, &amp;lt;1-year-olds collectively with atypical teratoid-rhabdoid tumor, and 1-19-year-olds with HGG (log rank p&amp;lt;0.02 for all tumor types). &amp;lt;3-month-olds were least likely to receive any treatment for each tumor type and least likely to undergo surgery for all except HGG. &amp;lt;1-year-olds were far less likely than 1-19-year-olds to undergo radiation for embryonal tumors, as expected, but were also less likely to undergo chemotherapy. CONCLUSIONS Congenital/infant CNS tumors differ pathologically, therapeutically, and prognostically from those in older children. Treatment changes could help address poorer outcomes for these young patients.
CSIG-04. ROLE OF c-Met/β1 INTEGRIN COMPLEX IN THE METASTATIC CASCADE
Authors: Sweta Sudhir, Darryl Lau, Harsh Wadhwa, Saket Jain, Ankush Chandra, Alan Nguyen, Jordan Spatz, Sumedh Shah, Justin Cheng, Michael Safaee, Garima Yagnik, Arman Jahangiri, Manish Aghi
Journal: Neuro-Oncology (2020)

Abstract Metastases cause 90% of human cancer deaths. The metastatic cascade involves 5 steps: local invasion, intravasation, extravasation, metastatic site colonization, and proliferation. While individual mediators of these processes have been investigated, interactions between these mediators remain less well defined. We previously identified a structural complex between receptor tyrosine kinase c-Met and β1 integrin in metastases that form under certain biological and therapeutic inducers, including bevacizumab. Using novel cell culture and in vivo assays, we found that c-Met/β1 complex induction promotes breast cancer intravasation and adhesion to the vessel wall but does not increase extravasation. These effects may be driven by the ability of the c-Met/β1 complex to increase mesenchymal and stem cell characteristics in breast cancer cells. Multiplex transcriptomic analysis revealed upregulated Wnt and hedgehog pathways after c-Met/β1 complex induction in breast cancer cells. We subsequently used CRISPR to introduce a β1 integrin point mutation that prevented binding to c-Met and led to reduced intravasation, confirming the importance of c-Met/β1 integrin binding for the metastatic cascade. OS2966, a therapeutic B1 integrin blocking antibody, disrupted c-Met/β1 binding as well, and decreased invasion, mesenchymal gene expression, and mesenchymal morphology of breast cancer cells. Bone-seeking breast cancer cells exhibited higher c-Met/β1 complex levels than parental controls and preferentially adhere to tissue-specific matrix. Patient bone metastases demonstrated higher c-Met/β1 complex levels than brain metastases. Thus, our research suggests the c-Met/β1 complex drives breast cancer cell intravasation and preferential affinity for bone tissue-specific matrix. Pharmacological targeting of the complex may prevent metastases, particularly osseous metastases.
The Updated US Preventive Services Task Force Hepatitis B Screening Recommendations—Staying Committed
Authors: Chelsea Q. Xu, Kali Zhou, Danielle Brandman
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract 11734: Weight Loss in the Management of Overweight and Obese Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis
Authors: Omar M Aldaas, Florentino Lupercio, Frederick T Han, Kurt S Hoffmayer, David Krummen, Gordon Ho, Farshad Raissi, Ulrika Birgersdotter-Green, Gregory K Feld, Jonathan C Hsu
Journal: Circulation (2019)

Background: Obesity and atrial fibrillation (AF) are growing epidemics with significant overlap in comorbidities. Multiple smaller studies have evaluated the effects of weight loss and risk factor ...
Short Telomeres Are Independent Prognostic Factors Associated with Poor Outcome in Chronic Lymphocytic Leukemia (CLL) Treated with Chlorambucil with or without the Addition of Rituximab or Obinutuzumab: Results from CLL11 Trial of the Gcllsg
Authors: Billy Michael Chelliah Jebaraj, Annika Scheffold, Sandra Robrecht, Jasmin Bahlo, Valentin Goede, Eugen Tausch, Sven Estenfelder, Veronika Opatrna, Matthias Ritgen, Jacques Jm van Dongen, Anton W Langerak, Günter Fingerle-Rowson, Michael Kneba, Kirsten Fischer, Michael J. Hallek, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood (2017)
LINC-29. IMPACT OF RELA FUSION ON OUTCOMES OF CHILDHOOD SUPRATENTORIAL EPENDYMOMAS (ST-EPEN)
Authors: Girish Chinnaswamy, Subramaniam Ramanathan, Maya Prasad, Tushar Vora, Ayushi Sahay, Mamta Gurav, Arpita Sahu, Aliasgar Moiyadi, Prakash Shetty, Jayant Sastri Goda, Rahul Krishnatry, Tejpal Gupta, Sridhar Epari
Journal: Neuro-Oncology (2020)

Abstract BACKGROUND Ependymomas are heterogenous group of tumours with variable clinical course and diverse molecular features. RELA fusion status has been reported to have prognostic impact in ST-EPEN. Our retrospective study analysed the prevalence and clinical impact of RELA fusion in childhood ST-EPEN at our centre. STUDY METHODS FFPE tissues of all childhood ST-EPEN diagnosed during 2011–2017 were evaluated for RELA fusion 1/2 by RT-PCR. Children were treated as per guidelines by the Neuro-oncology multidisciplinary team. Outcomes were correlated with RELA fusion, histological features and immunohistochemical parameters(L1CAM expression and Mib-1 index). Only patients with therapy details were included. RESULTS A total of 37 patients(0–50 years) with ST-EPEN were included(median age-10.2 years; boy:girl ratio-1.4:1)for analysis. Histological grade II, II/III and III was seen in 4(11%),2(5%) and 31(84%) patients respectively. Mib-1 index was assessable in 33 patients of which, 9 patients (24%) had a Mib-1 index &amp;gt;20%. RELA fusion was detected in 13(35%)tumors. The 3-year and 5-year EFS/OS of the overall cohort was 64.2%/83.6% and 60.1%/73.1% respectively. The 3-year/5-year EFS of RELA-positive tumors was inferior compared to RELA-negative tumours (53.8%/36% v/s 62.6%/53.6%; p=0.391). The 3-year/5-year EFS of tumors expressing L1CAM versus negative-expression was comparable (61.1%/55%v/s59.8%/47.9%;p=0.44). Presence of Mib-1&amp;gt;20% correlated with inferior survival (5-year EFS:81.1%vs22.2%; p&amp;lt;0.01). CONCLUSIONS ST-EPEN with RELA fusion had trend towards increased relapse/progression. High Mib-1 correlated with poor survival. RELA fusion status needs to be studied in a larger cohort prospectively to confirm its clinical impact.
LINC-35. THE ST. JUDE GLOBAL ACADEMY NEURO-ONCOLOGY TRAINING SEMINAR: A MULTIDISCIPLINARY, INTERNATIONAL EDUCATION PROGRAM
Authors: Daniel Moreira, Zoltan Patay, Frederick Boop, Jason Chiang, Thomas Merchant, Teresa Santiago, Amar Gajjar, Carlos Rodriguez-Galindo, Ibrahim Qaddoumi
Journal: Neuro-Oncology (2020)

Abstract The success of the treatment of children with central nervous system (CNS) tumors relies on an effective multidisciplinary team, with up-to-date and broad knowledge and skills. The St. Jude Global Academy Neuro-Oncology Training Seminar was launched as course in globally applicable content in pediatric neuro-oncology with a focus on multidisciplinary teams in low- and middle-income countries (LMICs). To identify the content that is most relevant for the learners, a needs assessment survey that included evaluation of team dynamics, treatment capacity, existing knowledge, and educational goals was designed. Survey questions in 11 domains were answered by 24 sites in LMICs across the world. This information was used to create the course that consists of two components: a 9-week online course and a 10-day workshop at the St. Jude campus. 72 participants from 11 institutions enrolled in the online portion and 20 participants were selected based on grades to attend the workshop. A retrospective post-test evaluation established that learners improved their understanding of the barriers to care, possible solutions to improve care, understanding of diagnosis and treatment, and methodology to implement projects (p&amp;lt;0.01). All participating teams developed projects that are locally implemented. Those present at the workshop formed a multidisciplinary, international collaborative group (Global Alliance in Pediatric Neuro-Oncology). This experience establishes that educational programs with systematically created curricula can not only improved knowledge but be a mechanism to share experiences and create collaborative networks. Ultimately, patient outcomes will be tracked to monitor the true impact of the course.
Visualized analysis of trends and hotspots in global oral microbiome research: A bibliometric study
Authors: Ga Liao, Jinyun Wu, Xian Peng, Yuqing Li, Li Tang, Xin Xu, Dongmei Deng, Xuedong Zhou
Journal: MedComm (2020)

The oral microbiome contains numerous bacteria, which directly or indirectly participate in various human functions and continuously exchange signals and substances with the human body, significantly affecting human life cycle, health, and disease. This study aimed to conduct bibliometric studies on the scientific outputs of global oral microbiome research by Citespace software. The data were obtained from the Thomson Reuters' Web of Science Core Collection (WoSCC), from the first relevant literature published until December 31st, 2019, and a total of 2225 articles and reviews were identified. The top country and institutions are the United States and Harvard University. Keywords analysis showed that periodontal disease, oral microbes, and dental plaque are research hotspots. The burst word analysis indicates that early childhood caries, squamous cell carcinoma, gut microbiome, Helicobacter pylori, Candida albicans, and dysbiosis are likely to become the research hotspots of the next era. We also recommend the use of knowledge mapping methods to track specific knowledge areas efficiently and objectively regularly, which can accurately identify hotspots and frontiers and provide valuable information for practitioners in the field, including related scientists, students, journals, and editors.
CTNI-50. NEUROCOGNITIVE FUNCTION (NCF) OF THE PHOTON COHORT IN NRG-BN001
Authors: Jeffrey S Wefel, Lyudmila DeMora, Vinai Gondi, Christina Tsien, Thomas Chenevert, Mark Gilbert, Antonio Omuro, Yue Cao, Ashok Srinivasan, Leland Rogers, Wenyin Shi, Lucien Nedzi, Michael Chan, John Suh, James Battiste, Mark Mishra, Anand Shivnani, Benjamin Movsas, Minesh Mehta
Journal: Neuro-Oncology (2020)

Abstract NRG BN001 is an ongoing randomized phase II trial of dose-intense (DI-RT) versus standard dose photon-based radiation therapy (SD-RT) with temozolomide (TMZ) for newly diagnosed glioblastoma. We report preliminary results of Group 1, DI-RT delivered with IMRT while SD-RT could be 3DCRT or IMRT. Group 2, DI-RT delivered with proton therapy, continues to accrue. From 10/2014 to 7/2018, 229 patients were eligible and randomized. Differences in overall survival following DI-RT versus SD-RT were not significant. Patients were scheduled to complete NCF testing at baseline, cycle 3 (within 7 days of cycle 4), and cycle 12 (day 22–28 of cycle 12, or 60 weeks from completion of chemoradiation). At baseline, 93–94% of eligible patients completed NCF testing. Compliance for evaluable patients at cycle 3 and cycle 12 was 66–68% and 51–54%, respectively, across the battery of NCF tests. The most common reasons for missing data were patient refusal (cycle 3: 14%, cycle 12: 22–23%) and institutional error (cycle 3: 9–10%, cycle 12: 14–15%). A prespecified secondary endpoint analysis was conducted to evaluate differences in NCF between SD-RT and DI-RT based on the Clinical Trial Battery Composite (CTB COMP), which is the mean of the standardized scores from the NCF test battery (HVLT-R, TMT, COWA). There was no statistically significant between arm difference in change from baseline on the CTB COMP at cycle 3 (DI-RT vs SD-RT mean/SD, 0.0 +/- 1.3 vs -0.3 +/- 1.5, p=0.370, Cohen’s d=0.22) or cycle 12 (DI-RT vs SD-RT mean/SD, 0.2 +/- 1.7 vs 0.2 +/- 1.1, p=0.977, Cohen’s d=0.01). A mixed effects longitudinal model of the CTB COMP yielded a non-significant time by treatment effect interaction (p=0.216). There were no significant differences in change scores between arms on any NCF test at cycles 3 or 12. NCF outcomes were similar for photon-based SD-RT and DI-RT.
On-Clopidogrel Platelet Reactivity: A Target in Sight?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Stephen D. Wiviott, Willibald Hochholzer
Journal: Journal of the American College of Cardiology (2011)
Association of Financial Hardship Because of Medical Bills With Adverse Outcomes Among Families of Children With Congenital Heart Disease
Authors: Avital B. Ludomirsky, Emily M. Bucholz, Jane W. Newburger
Journal: JAMA Cardiology (2020)

<h3>Importance</h3> Congenital heart disease (CHD) carries significant health care costs and out-of-pocket expenses for families. Little is known about how financial hardship because of medical bills affects families' access to essential needs or medical care. <h3>Objective</h3> To assess the national prevalence of financial hardship because of medical bills among families of children with CHD in the US and the association of financial hardship with adverse outcomes. <h3>Design, Setting, and Participants</h3> This cross-sectional survey study used data on children 17 years and younger with self-reported CHD from the National Health Interview Survey of US households between 2011 and 2017. Data were analyzed from March 2019 to April 2020. <h3>Exposures</h3> Financial hardship because of medical bills was classified into 3 categories: no financial hardship, financial hardship but able to pay medical bills, and unable to pay medical bills. <h3>Main Outcomes and Measures</h3> Food insecurity, delayed care because of cost, and cost-related medication nonadherence. <h3>Results</h3> Of 188 families of children with CHD (weighted sample of 151 537 families), 48.9% reported some financial hardship because of medical bills, with 17.0% being unable to pay their medical bills at all. Compared with those who denied financial hardships because of medical bills, families who were unable to pay their medical bills reported significantly higher rates of food insecurity (61.8% [SE, 11.0] vs 13.6% [SE, 4.0];<i>P</i> &lt; .001) and delays in care because of cost (26.2% [SE, 10.4] vs 4.8% [SE, 2.5];<i>P</i> = .002). Reported medication adherence did not differ across financial hardship groups. After adjusting for age, race/ethnicity, and maternal education, the differences between the groups persisted. The association of financial hardship with adverse outcomes was stronger among patients with private insurance than those with Medicaid. <h3>Conclusions and Relevance</h3> In this study, financial hardship because of medical bills was common among families of children with CHD and was associated with high rates of food insecurity and delays in care because of cost, suggesting possible avenues for intervention.
Natural IgM antibodies inhibit microvesicle-driven coagulation and thrombosis
Authors: Georg Obermayer, Taras Afonyushkin, Laura Göderle, Florian Puhm, Waltraud Schrottmaier, Soreen Taqi, Michael Schwameis, Cihan Ay, Ingrid Pabinger, Bernd Jilma, Alice Assinger, Nigel Mackman, Christoph J. Binder
Journal: Blood (2020)
Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab<i>versus</i>professional-collected nasopharyngeal swab
Authors: Andreas K. Lindner, Olga Nikolai, Franka Kausch, Mia Wintel, Franziska Hommes, Maximilian Gertler, Lisa J. Krüger, Mary Gaeddert, Frank Tobian, Federica Lainati, Lisa Köppel, Joachim Seybold, Victor M. Corman, Christian Drosten, Jörg Hofmann, Jilian A. Sacks, Frank P. Mockenhaupt, Claudia M. Denkinger
Journal: European Respiratory Journal (2020)

<b>Supervised nasal self-sampling is a reliable alternative to professional nasopharyngeal sampling using a WHO-listed SARS-CoV-2 antigen-detecting rapid test. Self-sampling and potentially patient self-testing may be a future use case.</b>https://bit.ly/3mup0hS
Defining a Bone Marrow Immune Signature Associated with Immunoglobulin Isotype Switching after Autologous Stem Cell Transplant
Authors: Rebecca Ye, Sirisha Kundrapu, Stanton L. Gerson, Rose Beck, James Driscoll, Suchitra Sundaram, Byung-Gyu Kim, Willem vanHeeckeren, Marcos De Lima, Ehsan Malek
Journal: Blood (2017)